Future studies of CBD in other psychotic conditions such as bipolar disorder and comparative studies of its antipsychotic effects with those produced by clozapine in schizophrenic patients are clearly indicated.
Evidence from several research domains suggests that CBD shows potential for antipsychotic treatment.
The results suggest that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia.
Behavioural and neurochemical models suggest that CBD has a pharmacological profile similar to that of atypical anti-psychotic drugs and a clinical trial reported that this cannabinoid is a well-tolerated alternative treatment for schizophrenia.
These results support the idea that CBD may be a future therapeutic option in psychosis, in general and in schizophrenia, in particular.
The results predominantly confirm the hypothesis of an antipsychotic activity of both cannabinoids. In comparison, cannabidiol appears to be superior to rimonabant with a pharmacological profile similar to atypical antipsychotic drugs.
CBD is a phytocannabinoid that is found in industrial hemp and marijuana, which are two different varieties of the Cannabis sativa plant.
CBD was as effective as amisulpride, a standard antipsychotic.
CBD monotherapy was not effective in treatment-resistant schizophrenia.